-
Mobocertinib succinate capsules approved for marketing with conditions
2023-01-11
Recently, the Class 1 innovative drug mobocertinib succinate capsule (trade name: 安卫力/EXKIVITY) of Takeda Pharmaceutical, Inc. is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
-
Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing
2023-01-04
Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:复邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA.
-
Importation of MSD's Molnupiravir Capsules approved with condition
2022-12-30
The importation registration of Molnupiravir Capsules (trade name: 利卓瑞/LAGEVRIO) for the treatment of COVID-19 of MSD Inc. is approved with condition for marketing by China NMPA on December 29, through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Provisions for Supervision and Administration of Online Drug Sales
2022-12-29
The Provisions for Supervision and Administration of Online Drug Sales is promulgated by Decree No. 58 of the State Administration for Market Regulation on August 3, 2022 and shall be effective as of December 1, 2022.
-
NMPA delegate elected co-chair of GHWP’s Technical Committee
2023-02-17
The meeting elected the technical committee office and the chairs and co-chairs of all working groups for the new term. Delegates of the NMPA participated in the election of the co-chair of the Technical Committee and chairs of Working Group 7 and Working Group 9.
-
Xu Jinghe elected chairman of GHWP
2023-02-17
On Feb 16, Xu Jinghe, deputy commissioner of China's National Medical Products Administration, was elected chairman of the 27th Global Harmonization Working Party in Riyadh, capital of Saudi Arabia.
